Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company ImmuCell has entered into a cross-license of technology agreement with Australia-based Anadis.
Subscribe to our email newsletter
ImmuCell granted Anadis an exclusive, worldwide license to the human and environmental applications of its milk antibody technology. Under this agreement, ImmuCell is not obligated to fund further product development and is entitled to receive a royalty on any sales achieved by Anadis utilizing the technology.
In return, ImmuCell was granted a license to the production technology and capabilities of Anadis in Australia. ImmuCell is obligated to pay Anadis a royalty on any sales of first defense manufactured in collaboration with Anadis in Australia.